Verrica Pharmaceuticals Inc. (VRCA)
$5.73+$0.66 (+12.96%) Today
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 6 | 42,230 | $211K |
| Grant or award | 7 | 981,449 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
24 Form 4 filings on record, the earliest from Oct 11, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David Zawitz - Officer | Open-market purchase | Common Stock | 6,000 | $4.98 | $30K | |
| Jayson Rieger - Officer | Open-market purchase | Common Stock | 20,000 | $5.06 | $101K | |
| Jayson Rieger - Officer | Open-market purchase | Common Stock | 5,000 | $4.91 | $25K | |
| Noah L. Rosenberg - Officer | Open-market purchase | Common Stock | 4,200 | $4.91 | $21K | |
| Noah L. Rosenberg - Officer | Open-market purchase | Common Stock | 2,030 | $4.92 | $10K | |
| John J. Kirby - Officer | Open-market purchase | Common Stock | 5,000 | $4.93 | $25K | |
 Lawrence Eichenfield | Grant or award | Stock Option (right to buy) | 16,000 | $0.00 | - | |
| Diem Nguyen | Grant or award | Stock Option (right to buy) | 16,000 | $0.00 | - | |
| Mark A. Prygocki Sr. | Grant or award | Stock Option (right to buy) | 16,000 | $0.00 | - | |
| Noah L. Rosenberg - Officer | Grant or award | Employee Stock Option (right to buy) | 233,840 | $0.00 | - | |
| David Zawitz - Officer | Grant or award | Employee Stock Option (right to buy) | 171,340 | $0.00 | - | |
| Jayson Rieger - Officer | Grant or award | Employee Stock Option (right to buy) | 512,269 | $0.00 | - | |
| Gavin Corcoran | Grant or award | Stock Option (right to buy) | 16,000 | $0.00 | - | |
| Noah L. Rosenberg - Officer | Open-market purchase | Common Stock | 2,357 | $4.24 | $10K | |
| Noah L. Rosenberg - Officer | Open-market purchase | Series C Warrant (right to buy) | 589 | - | - | |
 Paul B. Manning | Open-market purchase | Common Stock | 1,375,380 | $4.24 | $5.84M | |
| Paul B. Manning | Open-market purchase | Common Stock | 2,750,762 | $4.24 | $11.67M | |
| Paul B. Manning | Open-market purchase | Series C Warrant (right to buy) | 343,845 | - | - | |
| Paul B. Manning | Open-market purchase | Series C Warrant (right to buy) | 687,690 | - | - | |
| David Zawitz - Officer | Open-market purchase | Common Stock | 10,000 | $4.24 | $42K | |
| David Zawitz - Officer | Open-market purchase | Series C Warrant (right to buy) | 2,500 | - | - | |
| Jayson Rieger - Officer | Open-market purchase | Common Stock | 94,311 | $4.24 | $400K | |
| Jayson Rieger - Officer | Open-market purchase | Series C Warrant (right to buy) | 23,577 | - | - | |
| John J. Kirby - Officer | Open-market purchase | Common Stock | 3,536 | $4.24 | $15K | |
| John J. Kirby - Officer | Open-market purchase | Series C Warrant (right to buy) | 884 | - | - | |
| Mark A. Prygocki Sr. | Grant or award | Stock Option (right to buy) | 20,000 | $0.00 | - | |
| David Zawitz - Officer | Grant or award | Employee Stock Option (right to buy) | 950,000 | $0.00 | - | |
| Paul B. Manning | Open-market purchase | Common Stock | 18,426,966 | - | - | |
| Paul B. Manning | Open-market purchase | Common Stock | 4,494,382 | - | - | |
| Paul B. Manning | Gift | Common Stock | 450,000 | $0.00 | - | |
| Paul B. Manning | Open-market purchase | Series A Warrants (right to buy) | 9,213,483 | - | - | |
| Paul B. Manning | Open-market purchase | Series B Warrants (right to buy) | 9,213,483 | - | - | |
| Paul B. Manning | Open-market purchase | Series A Warrants (right to buy) | 2,247,191 | - | - | |
| Paul B. Manning | Open-market purchase | Series B Warrants (right to buy) | 2,247,191 | - | - | |
| Jayson Rieger - Officer | Open-market purchase | Common Stock | 280,898 | - | - | |
| Jayson Rieger - Officer | Gift | Common Stock | 50,000 | $0.00 | - | |
| Jayson Rieger - Officer | Open-market purchase | Series A Warrants (right to buy) | 140,449 | - | - | |
| Jayson Rieger - Officer | Open-market purchase | Series B Warrants (right to buy) | 140,449 | - | - | |
| John A. Stalfort III | Open-market purchase | Common Stock | 1,123,595 | - | - | |
| John A. Stalfort III | Gift | Common Stock | 50,000 | $0.00 | - | |
| John A. Stalfort III | Open-market purchase | Series A Warrants (right to buy) | 561,797 | - | - | |
| John A. Stalfort III | Open-market purchase | Series B Warrants (right to buy) | 561,797 | - | - | |
| Jayson Rieger - Officer | Grant or award | Employee Stock Option (right to buy) | 2,000,000 | $0.00 | - | |
| John J. Kirby - Officer | Grant or award | Common Stock | 54,267 | $0.00 | - | |
| Christopher G. Hayes - Officer | Grant or award | Employee Stock Option (right to buy) | 50,000 | $0.00 | - |
Verrica Pharmaceuticals Inc. (VRCA) had 11 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for VRCA runs to 24 Form 4 filings, the earliest from 2024-10-11. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
6 insider purchases of VRCA were filed in the last 90 days, totaling $211K.
No insider sales of VRCA were filed in the last 90 days.
This page tracks VRCA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add VRCA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
